AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events

    AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events

PR Newswire

REDWOOD CITY, Calif., July 1, 2013

REDWOOD CITY, Calif., July 1, 2013 /PRNewswire/ --AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that on July 9, 2013 the Company
will participate in the Piper Jaffray Catalyst Symposium in Boston MA and on
July 10, 2013, Richard King, President and CEO, will present a corporate
overview at the JMP Securities Healthcare Conference 2013 at the St. Regis New
York in New York, NY. Details of these two events are as follows:

Piper Jaffray Catalyst Symposium: Emerging Talent in BioPharma
Date: Tuesday, July 9, 2013
Location: Ritz-Carlton Boston Common, Boston, MA

JMP Securities Healthcare Conference 2013
Date: Wednesday, July 10, 2013
Location: The St. Regis New York in NY, NY
Presentation Time: 12:30 pm ET, 9:30 am PT

The JMP presentation will be webcast live and can be accessed through the
Investors page at www.acelrx.com. For those not available to listen to the
live broadcast, a replay of the presentations will be archived for 90 days and
available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. Zalviso™, AcelRx's lead product
candidate, is designed to solve the problems associated with post-operative
intravenous patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine, the
invasive IV route of delivery and the complexity of infusion pumps. Zalviso
has successfully completed all three of its planned Phase 3 clinical trials
and a New Drug Application submission is planned for the third quarter of
2013. AcelRx has announced positive top-line results for a Phase 2 trial for
ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute
pain, funded through a grant from U.S. Army Medical Research and Materiel
Command.The Company has two additional pain treatment product candidates,
ARX-02 and ARX-03, which have completed Phase 2 clinical development. For
additional information about AcelRx's clinical programs please visit
www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not
limited to, statements related to Zalviso, and the therapeutic potential of
AcelRx Pharmaceuticals' product candidates, the Company's planned New Drug
Application submission, planned or anticipated future clinical development of
AcelRx Pharmaceuticals' product candidates, and the therapeutic potential of
AcelRx Pharmaceuticals' product candidates.These forward-looking statements
are based on AcelRx Pharmaceuticals' current expectations and inherently
involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to: the
success, cost and timing of AcelRx Pharmaceuticals' product development
activities and clinical trials; the market potential for its product
candidates; and other risks detailed in the "Risk Factors" and elsewhere in
AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings,
including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2013.
AcelRx Pharmaceuticals undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of new
information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Jim Welch, Chief Financial Officer, 650.216.3511, jwelch@acelrx.com
 
Press spacebar to pause and continue. Press esc to stop.